Avita Medical (RCEL) Expected to Post Quarterly Earnings on Thursday

by · The Cerbat Gem

Avita Medical (NASDAQ:RCEL – Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.2394) per share and revenue of $22.35 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The firm had revenue of $21.70 million for the quarter, compared to analyst estimates of $20.25 million. On average, analysts expect Avita Medical to post ($0.98) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Avita Medical Stock Performance

Shares of Avita Medical stock traded up $0.60 on Tuesday, hitting $16.01. The stock had a trading volume of 64,308 shares, compared to its average volume of 327,081. The stock has a 50 day moving average of $12.31 and a 200 day moving average of $6.60. The firm has a market capitalization of $492.76 million, a P/E ratio of -10.92 and a beta of 1.99. Avita Medical has a twelve month low of $3.22 and a twelve month high of $16.90.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on RCEL shares. TD Cowen raised their price target on shares of Avita Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 19th. Lake Street Capital boosted their price objective on shares of Avita Medical from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, August 28th. Wall Street Zen upgraded Avita Medical from a “sell” rating to a “hold” rating in a report on Sunday, August 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Finally, BTIG Research raised their target price on Avita Medical from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.20.

Check Out Our Latest Research Report on RCEL

About Avita Medical

(Get Free Report)

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.

Featured Articles